Cargando…
Development of a biofilm inhibitor molecule against multidrug resistant Staphylococcus aureus associated with gestational urinary tract infections
Urinary Tract Infection (UTI) is a globally widespread human infection caused by an infestation of uropathogens. Eventhough, Escherichia coli is often quoted as being the chief among them, Staphylococcus aureus involvement in UTI especially in gestational UTI is often understated. Staphylococcal acc...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4531255/ https://www.ncbi.nlm.nih.gov/pubmed/26322037 http://dx.doi.org/10.3389/fmicb.2015.00832 |
_version_ | 1782385017678200832 |
---|---|
author | Balamurugan, P. Hema, M. Kaur, Gurmeet Sridharan, V. Prabu, P. C. Sumana, M. N. Princy, S. Adline |
author_facet | Balamurugan, P. Hema, M. Kaur, Gurmeet Sridharan, V. Prabu, P. C. Sumana, M. N. Princy, S. Adline |
author_sort | Balamurugan, P. |
collection | PubMed |
description | Urinary Tract Infection (UTI) is a globally widespread human infection caused by an infestation of uropathogens. Eventhough, Escherichia coli is often quoted as being the chief among them, Staphylococcus aureus involvement in UTI especially in gestational UTI is often understated. Staphylococcal accessory regulator A (SarA) is a quorum regulator of S. aureus that controls the expression of various virulence and biofilm phenotypes. Since SarA had been a focussed target for antibiofilm agent development, the study aims to develop a potential drug molecule targeting the SarA of S. aureus to combat biofilm associated infections in which it is involved. In our previous studies, we have reported the antibiofilm activity of SarA based biofilm inhibitor, (SarABI) with a 50% minimum biofilm inhibitory concentration (MBIC(50)) value of 200 μg/mL against S. aureus associated with vascular graft infections and also the antibiofilm activity of the root ethanolic extracts of Melia dubia against uropathogenic E. coli. In the present study, in silico design of a hybrid molecule composed of a molecule screened from M. dubia root ethanolic extracts and a modified SarA based inhibitor (SarABI(M)) was undertaken. SarABI(M) is a modified form of SarABI where the fluorine groups are absent in SarABI(M). Chemical synthesis of the hybrid molecule, 4-(Benzylamino)cyclohexyl 2-hydroxycinnamate (henceforth referred to as UTI Quorum-Quencher, UTI(QQ)) was then performed, followed by in vitro and in vivo validation. The MBIC(50) and MBIC(90) of UTI(QQ) were found to be 15 and 65 μg/mL, respectively. Confocal laser scanning microscopy (CLSM) images witnessed biofilm reduction and bacterial killing in either UTI(QQ) or in combined use of antibiotic gentamicin and UTI(QQ). Similar results were observed with in vivo studies of experimental UTI in rat model. So, we propose that the drug UTI(QQ) would be a promising candidate when used alone or, in combination with an antibiotic for staphylococcal associated UTI. |
format | Online Article Text |
id | pubmed-4531255 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-45312552015-08-28 Development of a biofilm inhibitor molecule against multidrug resistant Staphylococcus aureus associated with gestational urinary tract infections Balamurugan, P. Hema, M. Kaur, Gurmeet Sridharan, V. Prabu, P. C. Sumana, M. N. Princy, S. Adline Front Microbiol Microbiology Urinary Tract Infection (UTI) is a globally widespread human infection caused by an infestation of uropathogens. Eventhough, Escherichia coli is often quoted as being the chief among them, Staphylococcus aureus involvement in UTI especially in gestational UTI is often understated. Staphylococcal accessory regulator A (SarA) is a quorum regulator of S. aureus that controls the expression of various virulence and biofilm phenotypes. Since SarA had been a focussed target for antibiofilm agent development, the study aims to develop a potential drug molecule targeting the SarA of S. aureus to combat biofilm associated infections in which it is involved. In our previous studies, we have reported the antibiofilm activity of SarA based biofilm inhibitor, (SarABI) with a 50% minimum biofilm inhibitory concentration (MBIC(50)) value of 200 μg/mL against S. aureus associated with vascular graft infections and also the antibiofilm activity of the root ethanolic extracts of Melia dubia against uropathogenic E. coli. In the present study, in silico design of a hybrid molecule composed of a molecule screened from M. dubia root ethanolic extracts and a modified SarA based inhibitor (SarABI(M)) was undertaken. SarABI(M) is a modified form of SarABI where the fluorine groups are absent in SarABI(M). Chemical synthesis of the hybrid molecule, 4-(Benzylamino)cyclohexyl 2-hydroxycinnamate (henceforth referred to as UTI Quorum-Quencher, UTI(QQ)) was then performed, followed by in vitro and in vivo validation. The MBIC(50) and MBIC(90) of UTI(QQ) were found to be 15 and 65 μg/mL, respectively. Confocal laser scanning microscopy (CLSM) images witnessed biofilm reduction and bacterial killing in either UTI(QQ) or in combined use of antibiotic gentamicin and UTI(QQ). Similar results were observed with in vivo studies of experimental UTI in rat model. So, we propose that the drug UTI(QQ) would be a promising candidate when used alone or, in combination with an antibiotic for staphylococcal associated UTI. Frontiers Media S.A. 2015-08-11 /pmc/articles/PMC4531255/ /pubmed/26322037 http://dx.doi.org/10.3389/fmicb.2015.00832 Text en Copyright © 2015 Balamurugan, Hema, Kaur, Sridharan, Prabu, Sumana and Princy. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Microbiology Balamurugan, P. Hema, M. Kaur, Gurmeet Sridharan, V. Prabu, P. C. Sumana, M. N. Princy, S. Adline Development of a biofilm inhibitor molecule against multidrug resistant Staphylococcus aureus associated with gestational urinary tract infections |
title | Development of a biofilm inhibitor molecule against multidrug resistant Staphylococcus aureus associated with gestational urinary tract infections |
title_full | Development of a biofilm inhibitor molecule against multidrug resistant Staphylococcus aureus associated with gestational urinary tract infections |
title_fullStr | Development of a biofilm inhibitor molecule against multidrug resistant Staphylococcus aureus associated with gestational urinary tract infections |
title_full_unstemmed | Development of a biofilm inhibitor molecule against multidrug resistant Staphylococcus aureus associated with gestational urinary tract infections |
title_short | Development of a biofilm inhibitor molecule against multidrug resistant Staphylococcus aureus associated with gestational urinary tract infections |
title_sort | development of a biofilm inhibitor molecule against multidrug resistant staphylococcus aureus associated with gestational urinary tract infections |
topic | Microbiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4531255/ https://www.ncbi.nlm.nih.gov/pubmed/26322037 http://dx.doi.org/10.3389/fmicb.2015.00832 |
work_keys_str_mv | AT balamuruganp developmentofabiofilminhibitormoleculeagainstmultidrugresistantstaphylococcusaureusassociatedwithgestationalurinarytractinfections AT hemam developmentofabiofilminhibitormoleculeagainstmultidrugresistantstaphylococcusaureusassociatedwithgestationalurinarytractinfections AT kaurgurmeet developmentofabiofilminhibitormoleculeagainstmultidrugresistantstaphylococcusaureusassociatedwithgestationalurinarytractinfections AT sridharanv developmentofabiofilminhibitormoleculeagainstmultidrugresistantstaphylococcusaureusassociatedwithgestationalurinarytractinfections AT prabupc developmentofabiofilminhibitormoleculeagainstmultidrugresistantstaphylococcusaureusassociatedwithgestationalurinarytractinfections AT sumanamn developmentofabiofilminhibitormoleculeagainstmultidrugresistantstaphylococcusaureusassociatedwithgestationalurinarytractinfections AT princysadline developmentofabiofilminhibitormoleculeagainstmultidrugresistantstaphylococcusaureusassociatedwithgestationalurinarytractinfections |